Please select the option that best describes you:
Topics:
Hematologic Malignancies • Bone Marrow Transplant • ALL • CAR-T • AYA • Hematology • Pediatric Oncology
What is your approach to AYA patients with B-cell ALL who relapse after CD19 CAR-T?
Answer from: at Academic Institution
This is a somewhat nuanced question based on when the patient relapsed after CAR-T, what CAR-T product they received, whether the patient prior received hematopoietic stem cell transplantation (HSCT), other salvage therapies that were prior received as well as number of prior relapses.
Multiple str...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
My approach differs based on whether or not the patient has had a prior allogeneic hematopoietic stem cell transplant (HSCT), and whether they relapse with CD19-positive (CD19+) or CD19-negative (CD19⁻) disease. For those patients who are transplant naive and have CD19+ relapse, the goal is to get...